Aurobindo Pharma gains 5% on acquisition of Sandoz's US business

The stock rallied 5% to Rs 732 on Thursday, extending its Wednesday's 2% gain on the BSE, after the company announced the acquisition of Sandoz's generic business in the US for $900 million.

from Latest News https://ift.tt/2Nqpk3a
https://ift.tt/eA8V8J https://ift.tt/2LUVdkd

• Tweet
• Share
• Share
• Share
• Share